Invasive sellar extraventricular neurocytoma: illustrative case Authors: Olivia E. Gilbert, Jacob A. Dillard, Deveney Franklin, Atil Y. Kargi, Jackson Vuncannon, Dominique M. O. Higgins Published: 2026 ABSTRACT BACKGROUNDSellar extraventricular neurocytomas are exceedingly rare neuronal tumors that closely mimic more common sellar lesions, including pituitary adenomas and craniopharyngiomas. Their clinical presentation, most often visual field deficits with variable hypopituitarism, and nonspecific imaging characteristics make preoperative diagnosis difficult. Because few cases have been reported, optimal management strategies and long-term outcomes remain incompletely defined.OBSERVATIONSA 40-year-old man presented with progressive bitemporal hemianopia, headaches, and partial hypopituitarism. MRI revealed a mixed cystic and solid sellar mass with cavernous sinus extension. He underwent endoscopic endonasal resection with the goal of maximal safe cytoreduction and optic decompression. Postoperatively, vision, headaches, and thyroid function improved. Histopathological analysis demonstrated a neurocytoma characterized by synaptophysin and chromogranin positivity, absence of pituitary hormone and glial fibrillary acidic protein expression, and a low Ki-67 proliferative index. A literature review demonstrated frequent cavernous sinus invasion and a measurable recurrence risk, particularly after subtotal resection.LESSONSSellar neurocytoma should be considered in the differential diagnosis of invasive sellar masses. Definitive diagnosis relies on immunohistochemical analysis demonstrating neuronal differentiation with low proliferative activity. Surgical management should prioritize maximal safe resection and optic decompression, avoiding aggressive cavernous sinus dissection. Adjuvant radiotherapy and long-term surveillance are essential when residual disease is present. https://thejns.org/doi/10.3171/CASE26205 Neurocytomas are rare neuronal tumors first described in 1982 by Hassoun and colleagues, who reported 2 intraventricular cases demonstrating neuronal differentiation and proposed the term “central neurocytoma.”1 The WHO Classification of Tumours of the Central Nervous System subsequently recognized these tumors as a distinct entity and identified them as grade 2 neoplasms.2,3 Central neurocytomas typically arise in the lateral ventricles near the foramen of Monro and predominantly affect young adults in the 3rd to 4th decades of life.4–6 Clinical presentation is most often related to obstructive hydrocephalus and elevated intracranial pressure, including headaches, nausea, and visual disturbances.7,8 Extraventricular neurocytomas (EVNs), recognized later, occur outside the ventricular system but share morphological and immunohistochemical features with central neurocytomas. They have been described in the cerebral hemispheres, spinal cord, hypothalamus, and sellar region.9,10 Sellar neurocytomas represent one of the rarest subsets of EVNs. They are frequently difficult to distinguish clinically and radiologically from pituitary macroadenomas, craniopharyngiomas, or meningiomas.11–16 We identified only 41 cases of sellar neurocytomas across 17 publications since 2009.4,7,11–25 Symptoms are usually attributable to mass effect, including headache, bitemporal hemianopsia, and hypopituitarism. Endocrine dysfunction is variable; while most tumors are nonfunctional, unusual presentations like syndrome of inappropriate antidiuretic hormone and Cushing’s disease have been described.18,19 Radiographic findings are typically nonspecific. On MRI, sellar neurocytomas are usually iso- to hypointense on T1-weighted images and variably hyperintense on T2-weighted images, with heterogeneous contrast enhancement. These characteristics overlap significantly with pituitary adenomas, complicating preoperative diagnosis. Cystic changes, calcification, and intratumoral hemorrhage have been described in some cases, further mimicking the appearance of pituitary adenomas or craniopharyngiomas.22,23 The tumors are generally well circumscribed, but invasion into the cavernous sinus or sphenoid sinus has been observed, complicating surgical planning.16 MR spectroscopy and advanced imaging techniques may provide additional diagnostic insights in the future.13,24 Histopathologically, sellar neurocytomas are composed of sheets or nests of small to medium uniform round cells with round or oval nuclei, fine chromatin, and scant cytoplasm, often set in a fibrillary or neuropil-like background.13,16,17 Mitotic figures are generally rare and necrosis absent in typical cases, although recurrent tumors may exhibit increased cellularity, mitotic activity, focal necrosis, and microvascular proliferation.16 Immunohistochemical analysis consistently shows strong expression of neuronal markers including synaptophysin, NeuN, and neurofilament protein, with additional positivity for calretinin, chromogranin A, MAP2, and α-internexin in some cases, while glial fibrillary acidic protein (GFAP) and pituitary hormones are negative.13,16,17 Variable or focal expression of TTF-1 and vasopressin has been reported, and Liu et al. further demonstrated uniform SSTR2 (somatostatin receptor 2) expression with negative SSTR5 (somatostatin receptor 5).17 Proliferation indices are usually low, with the Ki-67 index around 1%–3% in typical cases but rising up to 10% in recurrent tumors.16 Electron microscopy has revealed dense tumor cell packing with neurosecretory granules, Golgi apparatus, polyribosomes, microfilaments, and hyaline globules called Herring bodies.17 Sellar neurocytomas are exceedingly rare neuronal tumors that remain a diagnostic challenge because of their clinical and radiological similarity to pituitary adenomas and other common sellar lesions. Further documentation and rigorous analysis of cases will be pivotal in understanding clinical behavior, informing management strategies, and distinguishing these tumors from other neurocytic neoplasms. We present an illustrative case of a sellar EVN highlighting its clinical, radiographic, and histopathological features, as well as multidisciplinary management considerations. Illustrative Case A 40-year-old male with a past medical history of depression, schizophrenia, and polysubstance abuse presented with a 3- to 4-year history of progressive, painless bilateral vision loss. The vision loss was more pronounced in the left eye than the right. He also reported difficulty with peripheral and long-distance vision, frequently bumping into objects due to visual field deficits. On review of systems, the patient reported erectile dysfunction worsening over the past year, particularly in recent months. He had occasional severe headaches occurring approximately once weekly. The patient denied changes in appetite, polyuria, polydipsia, cold or heat intolerance, galactorrhea, or other symptoms of pituitary dysfunction. On ophthalmological examination, the patient demonstrated severe bitemporal visual field deficits on confrontation testing. His extraocular movements were intact and without pain. His visual acuity was 20/50 in the right eye; it was unable to be assessed in the left eye due to shadows. In the left eye, he had an afferent pupillary defect and inability to identify any Ishihara color plates. Optical coherence tomography demonstrated thinning of the retinal nerve fiber layer (mean thickness: right eye 74 μm, left eye 62 μm) and ganglion cell layer (right eye 64 μm, left eye 53 μm). Humphrey visual field testing revealed a mean deviation of −25.22 dB in the right eye with a temporal altitudinal defect. Pertinent Laboratory Studies Endocrine assessment demonstrated abnormal gonadotroph and thyrotroph function, most consistent with hypopituitarism, although peripheral etiologies cannot be excluded. The results were as follows: low testosterone (24 ng/dL, reference range 197–670 ng/dL), low free T4 (0.84 ng/dL, reference range 0.89–1.76 ng/dL), normal thyroid-stimulating hormone (TSH) (0.808 μIU/mL, reference range 0.550–4.780 μIU/mL), normal T3 (total 97.0 ng/dL, reference range 60.0–180.0 ng/dL), normal adrenocorticotropic hormone (ACTH) (22 pg/mL, reference range 7.2–63 pg/mL for morning collection), normal growth hormone (0.06 ng/mL, reference range 0.01–0.97 ng/mL), and normal prolactin (14.5 ng/mL, reference range 2.1–17.7 ng/mL in males). Imaging Preoperative MRI of the brain with and without contrast (March 2025) showed a large sellar mass measuring 3.8 × 1.5 × 3.5 cm with suprasellar extension causing compression of the optic chiasm and optic nerves (Fig. 1). The mass extended into the bilateral cavernous sinuses (left greater than right) with encasement of the left cavernous internal carotid artery. The left cavernous sinus component caused partial effacement of the left Meckel’s cave and focal indentation of the left parahippocampal gyrus. There was increased T2/STIR signal intensity and atrophy of the left optic nerve. The superior portion of the tumor demonstrated both solid and cystic components and abutted the third ventricle. Imaging characteristics were initially thought to be most suggestive of pituitary macroadenoma, with craniopharyngioma in the differential diagnosis. FIG. 1.Preoperative midsagittal (A), coronal (B), and axial (C) MR images of the brain with and without contrast, demonstrating a large, heterogeneously enhancing sellar mass measuring 3.8 × 1.5 × 3.5 cm with suprasellar extension causing compression of the optic chiasm and optic nerves. Preoperative midsagittal (A), coronal (B), and axial (C) MR images of the brain with and without contrast, demonstrating a large, heterogeneously enhancing sellar mass measuring 3.8 × 1.5 × 3.5 cm with suprasellar extension causing compression of the optic chiasm and optic nerves. Given the profound visual symptoms attributed to compressive optic neuropathy from the sellar mass, surgical intervention was indicated for both diagnostic and therapeutic purposes. Intraoperative Course An endoscopic endonasal transsphenoidal approach was performed with image-guided navigation. Following bilateral nasal preparation and exposure, a common sphenoid cavity was created. The anterior sellar face and floor were removed to expose the dura, which was then opened sharply in a cruciate manner. Intraoperatively, the tumor demonstrated heterogeneous consistency, with pockets of soft tumor interspersed with large fibrotic components. The tumor was internally debulked, and both the right and left lateral cavernous sinuses were visualized along with the sellar floor and dorsum sella. The suprasellar component was then addressed; however, the fibrotic suprasellar tumor could not be separated from the surrounding dura and arachnoid without significant risk of neurovascular injury. Given extensive invasion into the bilateral cavernous sinuses (particularly on the left with encasement of the left internal carotid artery), a maximal safe resection strategy was used that focused on achieving optic apparatus decompression. Meticulous hemostasis was obtained, and the cavity was copiously irrigated. A high-flow CSF leak was identified and repaired with DuraGen inlay graft and nasoseptal flap reconstruction, secured with Surgicel, Gelfoam, and NasoPore packing. Frozen-section analysis was performed with final pathological interpretation deferred to permanent sections. The patient tolerated the procedure well and was extubated in the operating room. Pathology Results Final diagnosis from the permanent pathology results was a sellar neurocytoma. The microscopic description included fragments of normocellular adenohypophysis along with fragments of a neuroendocrine-appearing neoplasm consisting of loose aggregates of tumor cells with moderate nuclear-to-cytoplasmic ratios and minimal nuclear atypia. There were no prominent nucleoli or significant mitotic activity (0–1 mitoses per 10 high-power fields). Immunohistochemistry Results Immunohistochemical analysis showed the following results: positive for synaptophysin and chromogranin; patchy positive for cytokeratin 8/18, cytokeratin AE1/AE2, Olig2, and neurofilament; scattered cells positive for S100; negative for GFAP, IDH1-R132, ACTH, prolactin, growth hormone, TSH, follicle-stimulating hormone, luteinizing hormone, GATA3, PIT-1, T-PIT, SF-1, and TTF-1; and a Ki-67 labeling index of 1%–2%. The immunohistochemical profile with positive synaptophysin and chromogranin, negative pituitary hormones and GFAP, and low Ki-67 index was consistent with neurocytoma. Given the differential diagnosis initially including null cell pituitary adenoma and metastatic well-differentiated neuroendocrine tumor, the case was sent for expert consultation to Mayo Clinic Laboratories, where the diagnosis of sellar neurocytoma was confirmed. Postoperative Course The patient did well postoperatively and was discharged home on postoperative day 3. He reported significant improvement in his headaches and bilateral visual function. Endocrine evaluation revealed improved hypothyroidism and hypogonadism function with replacement therapy. There were no sinonasal complications. Postoperative MRI of the brain (Fig. 2) was completed for radiation planning of the residual tumor. The patient completed stereotactic radiation therapy (intensity-modulated radiation therapy and volumetric modulated arc therapy) at 5040 cGy over 28 fractions. At the 11-month follow-up, he remains clinically stable and without signs of radiographic recurrence or visual deterioration. FIG. 2.Postoperative midsagittal (A), coronal (B), and axial (C) MR images of the brain with and without contrast, demonstrating expected residual tumor, mostly in the left more than right cavernous sinuses and suprasellar area, and decreased mass effect on the optic apparatus. Postoperative midsagittal (A), coronal (B), and axial (C) MR images of the brain with and without contrast, demonstrating expected residual tumor, mostly in the left more than right cavernous sinuses and suprasellar area, and decreased mass effect on the optic apparatus. Informed Consent The necessary informed consent was obtained in this study. Discussion Observations This case highlights several strengths in the management of a rare sellar EVN. The MRI findings of a large sellar mass with both cystic and solid components, suprasellar extension, and bilateral cavernous sinus invasion are consistent with the invasive behavior described in the literature.16,22,23 The initial radiographic impression of pituitary macroadenoma reflects the diagnostic challenge these tumors pose, as they are frequently misdiagnosed preoperatively as adenomas or craniopharyngiomas.11–16 Preoperative recognition of extensive cavernous sinus invasion allowed the surgical team to pursue a realistic strategy focused on optic chiasm decompression and tissue diagnosis, avoiding aggressive gross-total resection that could have risked vascular injury or new cranial neuropathies. Initial diagnostic uncertainty on frozen and preliminary permanent sections prompted consultation with an internationally recognized neuropathologist, ensuring accurate pathological diagnosis. Our case demonstrated classic histopathological features including sheets of uniform cells with minimal atypia, rare mitoses (0–1 mitoses per 10 high-power fields), and the characteristic immunohistochemical profile.13,16,17 The strong positivity for synaptophysin and chromogranin with negative pituitary hormones and GFAP distinguished the tumor from pituitary adenoma and glioma. The Ki-67 labeling index of 1%–2% is consistent with reported values in typical sellar neurocytomas (generally 1%–3%), contrasting with higher indices (up to 10%) seen in recurrent or atypical cases.16 While molecular testing was not performed in our case, in a recent study Liu et al. identified LMCD1-AS1:GRM7-AS1 fusion transcripts in 80% of sellar neurocytomas studied.17 Transcriptomic analysis demonstrated overexpression of several hypothalamic hormones, including vasopressin, prolactin, oxytocin, and corticotropin-releasing hormone, further supporting a molecular profile distinct from both central neurocytomas and EVNs at other sites.17 Zhang et al. reported that tumors in this region lack many of the canonical alterations seen in related entities, including FGFR1 rearrangements, IDH mutations, BRAF V600E, TERT promoter mutations, and 1p/19q codeletion.16 Future cases may benefit from molecular characterization to better define the entity. Resection remains the cornerstone of treatment.15,17,23,25 The limitations of our patient’s surgery included the bilateral cavernous sinus invasion and left internal carotid artery encasement, necessitating radiotherapy and ongoing surveillance. Our experience with subtotal resection followed by adjuvant stereotactic radiotherapy aligns with management strategies reported in the literature for incompletely resected cases.15,25 While gross-total resection is associated with more favorable outcomes, complete removal is often technically challenging given the propensity for cavernous sinus invasion. Several series report recurrence rates of approximately 18% (7 of 38 cases in our literature review), typically following subtotal resection, supporting our decision for adjuvant radiotherapy.16,17 Given the extent of residual disease following subtotal resection, the role of adjuvant chemotherapy warrants discussion. Currently, there is no established chemotherapy regimen for sellar neurocytomas, and the literature provides limited guidance on systemic therapy for these rare tumors. Most reported cases have been managed with surgery alone or surgery plus radiotherapy, similar to our approach. Chemotherapy has been explored in recurrent central neurocytomas with agents such as temozolomide, etoposide, and platinum-based regimens, although responses have been variable and no standard protocol exists.26–28 In our patient’s case, the low Ki-67 proliferation index (1%–2%), absence of atypical histological features, and initial radiographic stability following stereotactic radiotherapy did not support immediate chemotherapy. However, given the propensity for recurrence after subtotal resection and the limited data on optimal adjuvant therapy for sellar neurocytomas, chemotherapy remains a consideration should progression occur despite radiotherapy. Future prospective studies and molecular characterization may help identify patients who could benefit from systemic therapy in addition to standard surgical and radiation approaches. In general, sellar neurocytomas demonstrate poorer outcomes compared to central neurocytomas, with lower rates of gross-total resection, higher recurrence rates, and shorter progression-free survival (mean 24 months in one series).14,17 Zhang et al. reported that 3 of 4 patients with subtotal resection experienced recurrence during long-term follow-up.16 Our patient’s 11-month radiographic and clinical stability is encouraging but underscores the need for continued surveillance. While most sellar neurocytomas behave as WHO grade 2 tumors, Kawaji et al. reported 1 case with spinal dissemination, demonstrating the potential for aggressive behavior.15 Our case showed no evidence of atypical features or dissemination. Lessons Sellar neurocytomas, although rare, should be considered in the differential diagnosis of sellar masses, particularly in younger to middle-aged adults presenting with visual disturbances and hypopituitarism. Preoperative imaging is nonspecific and cannot reliably distinguish these tumors from pituitary adenomas or craniopharyngiomas, making tissue diagnosis essential. Immunohistochemical analysis is diagnostic, with positive neuronal markers such as synaptophysin and chromogranin, negative pituitary hormones and GFAP, and a low Ki-67 index; expert neuropathology consultation may be helpful in challenging cases. Given the propensity for cavernous sinus invasion, surgical management should prioritize maximal safe resection and optic decompression rather than aggressive pursuit of gross-total resection, which risks vascular or cranial nerve injury. Adjuvant stereotactic radiotherapy should be considered in cases of subtotal resection or recurrence given the documented recurrence risk. Long-term, potentially lifelong MRI and clinical surveillance is warranted, particularly after subtotal resection. Multidisciplinary management involving the neurosurgery, endocrinology, ophthalmology, and radiation oncology teams optimizes outcomes, and evolving molecular characterization may further refine prognosis and guide future multidisciplinary therapeutic strategies. We present a case of sellar neurocytoma in a 40-year-old male who presented with progressive bilateral vision loss and partial hypopituitarism. Following endoscopic endonasal transsphenoidal resection and expert neuropathological consultation confirming the diagnosis, the patient underwent adjuvant stereotactic radiotherapy for residual disease. At the 11-month follow-up, he remained clinically and radiographically stable with improved visual symptoms and optimized endocrine function. This case adds to the limited literature on sellar neurocytomas and highlights the importance of maintaining this rare entity in the differential diagnosis of sellar masses, utilizing immunohistochemical analysis for accurate diagnosis, using appropriate surgical strategies given the invasive nature of these tumors, and implementing adjuvant radiotherapy for incompletely resected cases. Continued reporting of cases with long-term follow-up will be essential to better define the natural history, optimize treatment strategies, and identify prognostic factors for this uncommon entity. Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. Author Contributions Conception and design: Gilbert, Franklin, Kargi, Higgins. Acquisition of data: Gilbert, Vuncannon, Higgins. Analysis and interpretation of data: Gilbert, Higgins. Drafting the article: Gilbert, Dillard, Higgins. Critically revising the article: Gilbert, Franklin, Kargi, Vuncannon, Higgins. Reviewed submitted version of manuscript: Gilbert, Dillard, Franklin, Vuncannon, Higgins. Approved the final version of the manuscript on behalf of all authors: Gilbert. Administrative/technical/material support: Higgins. Correspondence Olivia E. Gilbert: University of North Carolina, Chapel Hill, NC. olivia.gilbert@unchealth.unc.edu.